No Detail Found!

Comparison of lipid profile improvements with low dose of rosuvastatin and simvastatin as lipid lowering drugs in high risk patients: A randomized clinical trial

Author(s)
Anjum Ilahi Al-Nafees Medical College & Hospital, Isra University, Islamabad Campus, Islamabad, Pakistan
Adnan Saleem Khan Al-Nafees Medical College & Hospital, Isra University, Islamabad Campus, Islamabad, Pakistan
Sadia Zainab Al-Nafees Medical College & Hospital, Isra University, Islamabad Campus, Islamabad, Pakistan
Mansur Ilahi Medical Testing and Research Organization (MTRO)
Abstract
Objective: To compare efficacy with percentage reduction in lipid profile of Rosuvastatin versus Simvastatin along with tolerability in patients of coronary artery disease. Study Design: A randomized clinical trial Setting: Cardiology Department of Medical Testing and Research Organization Islamabad from 1st October till 1st December 2016. Methodology: A total of one hundred six patients with coronary artery disease were randomized into two equal groups to give Rosuvastatin 5mg to group I and Simvastatin 20mg to group II for eight weeks. As per guidelines of treatment of dyslipidemia the primary outcome was to lower LDLC< 100mg/dl. Secondary treatment outcomes were reduction of Total Cholesterol, elevation in HDL-Cholesterol and tolerability of both drugs. Results: Rosuvastatin Group consisted of 62.3% males and 37.7% females while Simvastatin Group had 56.6% males and 43.4% females. Patients aged 55.20 ± 7.16 years in group I and 56.83 ± 6.30 years in group II. Primary treatment outcome was attained in patients of Rosuvastatin Group 75.5% as paralleled to Simvastatin 47.2%. Reduction in LDL-C from initial and terminal analyses showed significant results (Rosuvastatin 44.2% whereas Simvastatin group 39.4%). Data produced by Rosuvastatin group revealed clinically significant decrease in total Cholesterol 37.6% as compared to Simvastatin group 28.2% while more rise in HDL-C was determined in Rosuvastatin group 16.9% than Simvastatin group 7.1 %. No serious adverse effects were found in both treatments groups. Conclusion: Rosuvastatin is more potent lipid modifying agent than Simvastatin and it has similarity to Simvastatin in tolerability.
Publication Details
Page(s) 141-145
DOI DOI not available
Published Journal: Isra Medical Journal, Volume: 11, Issue: 3, Year: 2019

Request the full text from PASTIC

Keywords
cholesterol, Dyslipidemia, Coronary artery disease, simvastatin, LDL Cholesterol, HDL Cholesterol.
0

Citations

0

Downloads

53

Views